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Abstract Salbutamol sulphate liposomes were generated using ethanol-
based proliposomes followed by nebulization using an Aeroneb Pro 
vibrating-mesh nebulizer. The droplet size, output and fine particle 
fraction (FPF) of the drug incorporated in liposome formulation were 
compared to those of a conventional drug solution. Aerosol output was 
determined gravimetrically and drug output was analyzed by using high 
performance liquid chromatography. The potential of aerosol deposition 
in deep lung was evaluated using inertial impaction and laser diffraction. 
The effect of formulation surface tension on the aerosol performance was 
studied. Output and FPF were improved using liposomes compared to the 
conventional solution, for instance, FPF values were 57.85% and 45.81% 
respectively. The volume median diameter as measured by laser diffraction 
was respectively 3.44 µm and 3.22 µm; however, the higher FPF of the 
liposome formulation is justified by the lower polydispersity of its aerosol. 
The improved aerosol performance using liposomes was attributed to the 
reduction of surface tension caused by the presence of phospholipid. This 
is the first study that demons trates the ability of liposomes to improve the 
nebulized drug output and FPF.
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1. INTRoDUCTIoN
Liposomes are phospholipid carrier vesicles that are made of materials which are very similar to the components of lung surfactants. Many studies have demonstrated that liposomes are generally safe for 
pulmonary delivery (Kellaway and Farr, 1990). Therapeutically, liposomes can 
prolong the action of the entrapped drug in the respiratory tract; hence they can 
potentially improve the therapeutic outcome and reduce the systemic adverse 
effects of the drug (Taylor et al., 1989; Saari et al., 1999; Weers et al., 2009). 
The main limitation of liposomes is their instability in aqueous dispersions, 
since phospholipids are liable to hydrolysis (Kensil and Dennis, 1981) and 
oxidation (Hunt and Tsang, 1981); this may cause the liposomes to aggregate 
or fuse, resulting in leakage of the drug originally entrapped. 
Freeze-drying (lyophilization) in the presence of suitable cryoprotectants 
has been used to resolve the problem of liposome instabilities (Gordon et al., 
1982; van Bommel and Crommelin, 1984; Crowe et al., 1986). Recently, we 
have shown that two antiasthma drugs can be included in small unilamellar 
liposome formulations using freeze-drying with sucrose or trehalose as 
cryoprotectants (Elhissi et al., 2010). Proliposome technologies are economical 
alternatives to freeze-drying. For instance, ethanol-based proliposomes are 
concentrated ethanolic solutions of phospholipid which generate liposomes by 
addition of aqueous phase and shaking (Perrett et al., 1991). The suitability of 
ethanol-based proliposomes to generate inhalable liposomes via nebulizers has 
been demonstrated (Elhissi et al., 2006; Elhissi et al., 20011).  
The therapeutic benefit of aerosols in pulmonary drug delivery is determined 
by the percentage of dose delivered in the “fine particle fraction” (FPF); the 
dose fraction which is delivered in aerosol particles smaller than 5-6 µm and 
is considered “respirable” and hence likely to reach the peripheral airways 
(i.e. bronchioles and alveolar region) (Stahhofen et al., 1980; O’Callaghan and 
Barry, 1997). 
Pulmonary delivery of “respirable” liposome aerosols is well-established 
using medical nebulizers (Knight and Gilbert, 1988; Taylor et al., 1989; Saari 
et al., 1999). Currently, there are three types of nebulizers: air-jet, ultrasonic 
and vibrating-mesh nebulizers (Elhissi and Ahmed, 2011). Whilst traditional 
ultrasonic nebulizers are generally unsuitable for delivery of liposomes (Elhissi 
and Taylor, 2005), air-jet nebulizers are superior in delivery of “respirable” 
liposome aerosols (Farr et al., 1985; Waldrep et al., 1993; Waldrep et al., 
1994; Saari et al., 1998; Saari et al., 1999; Albasarah et al., 2010). However, 
the shearing occurring within air-jet nebulizers may damage the liposome 
bilayers, resulting in considerable losses of entrapped hydrophilic materials 
(Taylor et al., 1990; Elhissi et al., 2007). The more recently commercialized 
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type of nebulizers, namely vibrating-mesh nebulizers (Dhand, 2002; Elhissi 
and Ahmed, 2011) are suitable for liposome delivery (Elhissi and Taylor, 
2005; Li et al., 2008; Gaspar et al., 2010; Elhissi et al., 2011; Elhissi et al., 
2012) and may cause less losses of the entrapped drug during aerosolization 
when compared to air-jet nebulizers (Elhissi et al., 2006; Elhissi et al., 2007; 
Kleemann et al., 2007). 
An example of vibrating-mesh nebulizers is the Aeroneb Pro device (Fig.1) 
which employs a perforated plate that is connected to a vibrational element, 
causing a “micropump” action which extrudes the medical fluid and generates 
the aerosol (Dhand, 2002; Ghazanfari et al., 2007). The aerosol properties 
of vibrating-mesh nebulizers are highly influenced by fluid physicochemical 
properties when conventional solutions are nebulized (Ghazanfari et al., 2007; 
Najlah et al., 2013). 
Salbutamol sulphate (Fig.2) is a selective short acting B2-adrenoceptor 
agonist that is widely used for the treatment of asthma. Using liposomes 
generated from ethanol-based proliposomes, the entrapment efficiency of this 
drug in liposomes may exceed 60% (Elhissi et al., 2006; Elhissi et al., 2011). In 
this study, the aerosol properties of salbutamol sulphate liposomes generated 
from proliposomes were compared to aerosols generated from a conventional 
drug solution using the micropump Aeroneb Pro vibrating-mesh nebulizer. 
This is the first study that evaluates the effect of liposomes on the aerosol 
properties of nebulizers in terms of output and FPF.
Figure 1. Design of the Aeroneb Pro vibrating-mesh nebulizer  
(Ghazanfari et al., 2007)
Figure 2. Chemical structure of salbutamol sulphate
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2. MATERIAls AND METhoDoloGy
2.1 Materials
Soya phosphatidylcholine (SPC; Lipoid S-100) was a gift from Lipoid, 
Switzerland. Salbutamol sulphate was purchased from Alfa Aesar, UK. Sodium 
chloride (NaCl) and absolute ethanol were of analytical grade “AnalaR” and 
supplied by VWR, UK. Cholesterol (99%), sodium hexane sulphonate, Triton 
X-100 were purchased from Sigma Aldrich, UK. Water and methanol used in 
high performance liquid chromatography (HPLC) were of HPLC grade and 
supplied by Fisher Scientific Ltd., UK. The Aeroneb Pro micropump nebulizer 
was supplied as a gift by Aerogen Ltd, Ireland.
2.2 Methods
2.2.1 Preparation of liposomes
The lipid phase (50 mg) consisting of SPC and cholesterol (1:1) was dissolved 
in ethanol (60 mg) with heating for 1 min at 60°C. This quantity of ethanol was 
found to be appropriate to dissolve the lipids (Elhissi et al., 2006). Salbutamol 
sulphate in NaCl (0.9%) solution (5 mg/ 100 µl) was added and formulation 
was mixed for 1 min to generate a “milky” dispersion of liposomes. The 
preparation was further diluted with 4.9 ml drug-free solution of NaCl (0.9%). 
This formulation was prepared by following the procedure conducted in our 
previous publications, and found to yield an entrapment efficiency exceeding 
60% for this drug (Elhissi et al., 2006; Elhissi et al., 2011). Surface tension 
measurements of liposome formulations and conventional salbutamol sulphate 
solution were performed using a Kibron Delta-8 multichannel microtensiometer 
(Kibron, Finland).  
2.2.2 Aerosol droplet size analysis
Droplet size and size distribution of aerosols generated with the Aeroneb 
Pro nebulizer were analyzed using the Malvern 2600c laser diffraction size 
analyzer (Malvern Instruments Ltd., UK) by recording the volume median 
diameter (VMD; 50% undersize) and Span values, respectively. Span = (90% 
undersize – 10% undersize) / VMD. 
2.2.3 Nebulizer output study and determination of FPF
A two-stage impinger was set up by placing 30 ml and 7 ml of NaCl (0.9%) 
solution in its lower and upper stages respectively. The flow rate through the 
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impinger was set up at 60 L/min. At this flow rate, the cut-off aerodynamic 
diameter between the upper and lower stages is 6.4 µm (Hallworth and 
Westmoreland, 1987). The Aeroneb Pro nebulizer (Aerogen Ltd, Ireland) was 
accurately weighed and filled with liposome dispersion or drug solution (5 
ml) and reweighed. The nebulizer was directed towards the “throat” of the 
impinger and nebulization was performed to “dryness” as determined by 30 
seconds after complete cessation of the aerosol generation. The nebulizer was 
weighed for the third time and the aerosol output was calculated by calculating 
the weight difference. The drug output and distribution between the upper 
and lower stages of the impinger were determined using HPLC according 
to the method previously described by Elhissi et al. (2006). The drug output 
was multiplied by the fraction of the drug deposited in the lower stage of the 
impinger (i.e. drug in aerosol droplet <6.4 µm) to calculate the FPF for each 
formulation. 
2.2.4 Statistical analysis
All experiments were conducted three times. Analysis of variance (ANOVA) 
and student’s t-tests were performed. When the calculated P value was less than 
0.05 the difference between the compared groups was considered statistically 
significant. 
3. REsUlTs AND DIsCUssIoN
3.1 surface tension of formulations
Table 1 shows that surface tension is significantly (P<0.05) affected by 
formulation, with liposome formulations having much lower surface tension 
when compared to lipid-free formulations. The presence of salbutamol sulphate 
or sodium chloride did not affect the measured surface tension (Table 1), 
Table 1. Surface tension measurements of formulations (n = 3 ±SD).
Formulation surface tension (mN/m)
Deionised water 72.32 ±0.44
NaCl (0.9%) 72.09 ±0.44
Drug solution 72.10 ±0.57
Liposomes (without drug) 31.63 ±1.95
Liposomes (with drug) 31.38 ±1.97
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indicating that the activity exerted on the surface by these salts was minimal 
and insignificant.
3.2 Nebulization performance study
The output study showed that both formulations had insignificantly (P>0.05) 
higher mass output than drug output (Fig.3a). The similarity between drug 
Figure 3. Aerosol mass and drug outputs from the Aeroneb Pro nebulizer (a) 
and drug distribution between the nebulizer reservoir and the impinger stages 
(b) using the conventional salbutamol sulphate solution and proliposome 
formulation (n = 3 ± SD).
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Table 2. Size and size distribution of aerosol droplets after 5 min 
nebulization using laser diffraction, and FPF as calculated  using the two-
stage impinger at the end of nebulization (n = 3 ±SD).
Formulation VMD (µm) span FPF (%)
Solution 3.22 ±0.02 2.16 ±0.04 45.81 ±1.03
Liposomes 3.44 ±0.05 1.98 ±0.05 57.85 ±0.75
output and aerosol output indicates that solvent evaporation from the nebulizer 
was minimal and the presence of liposomes did not hinder the delivery of the 
drug. By contrast, previous studies have demonstrated that air-jet nebulizers 
cause solvent evaporation during nebulization and concentrate the soluble 
material within nebulizer reservoir (McCallion et al., 1996). Aerosol mass 
output and drug output were significantly (P<0.05) higher for the liposomal 
preparation compared to the conventional solution (Fig.3a), indicating that 
the inclusion of phospholipid was desirable, probably because phospholipid 
reduced the surface tension of formulation (Table 1). This clearly demonstrates 
a novel application of liposomes in nebulizer formulations. 
Liposomes also significantly (P<0.05) increased the fraction of drug 
delivered to the lower impinge stage and decreased the deposition in the upper 
stage of the impinger (Fig.3b). This suggests that nebulized liposomes may 
not only offer a sustained and localized drug effect in the respiratory airways 
(Taylor et al., 1989; Saari et al., 1999; Weers et al., 2009) but can also increase 
the dose delivered in “respirable” fraction. Thus, liposomes may play roles 
beyond entrapment of drugs when the Aeroneb Pro vibrating-mesh nebulizer 
is employed, with inclusion of lipid having a desirable effect on drug delivery 
and deposition in the “FPF”. 
The liposomal preparation produced aerosol droplets of larger VMD 
(P<0.05) and smaller Span (P<0.05) (Table 2). Thus, the higher deposition in 
the lower stage impinger of the liposomal formulation (Fig.3b) was attributed 
to the narrower size distribution (i.e. lower polydispersity) of the aerosols when 
phospholipid was included within formulations (Table 2). This was attributed 
to the lower surface tension of the fluid as a result of lipid inclusion (Table 
1). Using Newtonian fluids, the droplet size and size distribution of aerosols 
generated using vibrating-mesh nebulizers were shown to be highly affected 
by the fluid physicochemical properties such as viscosity, surface tension 
(Ghazanfari et al., 2007) and inclusion of ions (Ghazanfari et al., 2007; Najlah 
et al., 2013). 
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4. CoNClUsIoN
This study has shown that an ethanol-based approach to generating liposomes 
can be used to prepare a salbutamol sulphate formulation with enhanced drug 
output and improved “FPF” compared to a conventional solution of the drug 
when nebulization was performed using the micropump Aeroneb Pro vibrating-
mesh nebulizer.
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